Dr. R. Michael Tuttle on New Horizons for Radioactive Iodine Treatment
R. Michael Tuttle, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, talks about the new horizons for radioactive iodine treatment in thyroid cancer.
R. Michael Tuttle, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, talks about the new horizons for radioactive iodine treatment in thyroid cancer. He says some new treatments, like the MAP kinase inhibitor and BRAF inhibitor, block pathways that would allow a cancerous thyroid tumor to concentrate radioiodine.
Tuttle says there are currently research groups, such as the one at Memorial Sloan Kettering Cancer Center, that are seeing great improvements in patients with thyroid cancer after a month of taking these inhibitors. Looking toward the future, Tuttle says he thinks the definition of how oncologists use radioactive iodine will change over the next 5 years.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
